the great plains laboratory, inc. | operating worldwide
The Great Plains Laboratory, Inc. is a world leader in providing testing for metabolic, genetic, mitochondrial, and environmental factors in chronic illnesses. We offer a variety of state-of-the-art metabolic and genetic tests such as the Organic Acids Test, GPL-TOX (Toxic Non-Metal Chemical Profile), IgG Food Allergies Test, and GPL-SNP1000, our DNA Sequencing Profile. Our ultimate goal is to help you provide your patients with the most personalized medicine possible and improve their quality of life. To find a specialist or to obtain a physician referral, contact our customer service department at 913-341-8949 or click here.
Free 30 minute phone consultations are available to assist in the interpretation of your test results.
Research has established that increased intake of processed sugars and fast-food consumption has been correlated with a higher risk for ADHD and behavioral disturbances in children. There is also evidence implicating the role of food sensitivities to proteins found in dairy and wheat that can trigger symptoms of irritability, hyperactivity, and impulsivity. This webinar will distinguish the clinical characteristics between food sensitivity vs. food allergy, and guide participants on how to interpret functional medicine testing results to make appropriate dietary and treatment recommendations.
There are many different diets to choose from for a special needs individual. Some diets work better than others for certain situations. Unfortunately, there is not a ‘one-size, fits all’ diet, but understanding how different diets work can often make the choice easier. This lecture will present important information about various biomedical diets.
PLA2, an enzyme found in snake and bee venom, as well as in human tissue, has been found to be elevated in a variety of inflammation-related disorders. It is considered a good marker for increased risk of developing or worsening inflammatory conditions including allergies, multiple sclerosis, cardiovascular disease (including atherosclerosis), Crohn’s disease, neurodegenerative diseases, bipolar depression, long term depression, schizophrenia, and sepsis. This presentation will review the new information available about PLA2, including an ongoing pilot study with MS patients, methods for PLA2 testing, and treatments that reduce PLA2 levels and inflammation.